Dose and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A Retrospective Study.

IF 2.5 4区医学 Q3 ONCOLOGY

Cancer Management and Research Pub Date : 2024-11-16 eCollection Date: 2024-01-01 DOI:10.2147/CMAR.S481289

Xuexue Bai, Hao Xing, Ming Feng, Wenbin Ma, Shiyong Wang

{"title":"Dose and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A Retrospective Study.","authors":"Xuexue Bai, Hao Xing, Ming Feng, Wenbin Ma, Shiyong Wang","doi":"10.2147/CMAR.S481289","DOIUrl":null,"url":null,"abstract":"Purpose: We retrospectively analyzed the effect of Bevacizumab (BEV) on recurrent high-grade glioma (rHGG) and examined the relationship between dose and efficacy.Methods: A total of 182 patients with rHGG were included in this study. Patients were divided into a non-BEV group and a BEV group according to the treatment they received, and the BEV group was further divided into a low-dose group and a high-dose group based on the dose. Depending on the number of groups and the characteristics of numerical variables, t-test, ANOVA, or rank-sum test were selected. Categorical variables were compared using the chi-squared test.Results: Progression-free survival (PFS) was lower in the non-BEV group compared to the BEV group, while overall survival (OS) was not different between the two groups. There was no difference in PFS and OS between low-dose group and high-dose group. Notably, we found that patients with longer PFS and OS were more likely to be from the BEV group. In addition, differences in Karnofsky Performance Score (KPS), steroid dose, and brain edema were observed in the non-BEV, low-dose, and high-dose groups from 3 to 12 months after treatment.Conclusion: BEV can improve PFS in patients with rHGG, although its impact on OS is limited. There was no difference in the efficacy of different doses of BEV on rHGG. Interestingly, patients with longer PFS and OS were more likely to be from the BEV group. Based on these findings, long-term low-dose BEV appears to be an effective treatment option for rHGG.","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"16 ","pages":"1617-1626"},"PeriodicalIF":2.5000,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11578801/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Management and Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/CMAR.S481289","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: We retrospectively analyzed the effect of Bevacizumab (BEV) on recurrent high-grade glioma (rHGG) and examined the relationship between dose and efficacy.

Methods: A total of 182 patients with rHGG were included in this study. Patients were divided into a non-BEV group and a BEV group according to the treatment they received, and the BEV group was further divided into a low-dose group and a high-dose group based on the dose. Depending on the number of groups and the characteristics of numerical variables, t-test, ANOVA, or rank-sum test were selected. Categorical variables were compared using the chi-squared test.

Results: Progression-free survival (PFS) was lower in the non-BEV group compared to the BEV group, while overall survival (OS) was not different between the two groups. There was no difference in PFS and OS between low-dose group and high-dose group. Notably, we found that patients with longer PFS and OS were more likely to be from the BEV group. In addition, differences in Karnofsky Performance Score (KPS), steroid dose, and brain edema were observed in the non-BEV, low-dose, and high-dose groups from 3 to 12 months after treatment.

Conclusion: BEV can improve PFS in patients with rHGG, although its impact on OS is limited. There was no difference in the efficacy of different doses of BEV on rHGG. Interestingly, patients with longer PFS and OS were more likely to be from the BEV group. Based on these findings, long-term low-dose BEV appears to be an effective treatment option for rHGG.

查看原文本刊更多论文

贝伐单抗治疗复发性高级别胶质瘤的剂量和疗效：一项回顾性研究。

目的：我们回顾性分析了贝伐单抗（BEV）对复发性高级别胶质瘤（rHGG）的疗效，并研究了剂量与疗效之间的关系：本研究共纳入182例rHGG患者。根据患者接受的治疗分为非BEV组和BEV组，BEV组又根据剂量分为低剂量组和高浓度组。根据组数和数字变量的特点，选择 t 检验、方差分析或秩和检验。分类变量的比较采用卡方检验：结果：与BEV组相比，非BEV组的无进展生存期（PFS）较低，而两组的总生存期（OS）无差异。低剂量组与高剂量组的无进展生存期和总生存期没有差异。值得注意的是，我们发现 PFS 和 OS 较长的患者更可能来自 BEV 组。此外，在治疗后 3 至 12 个月，我们还观察到非 BEV 组、低剂量组和高剂量组在卡诺夫斯基表现评分（KPS）、类固醇剂量和脑水肿方面的差异：结论：BEV可改善rHGG患者的PFS，但对OS的影响有限。不同剂量的 BEV 对 rHGG 的疗效没有差异。有趣的是，PFS 和 OS 较长的患者更可能来自 BEV 组。基于这些研究结果，长期低剂量 BEV 似乎是治疗 rHGG 的有效选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Management and Research Medicine-Oncology

CiteScore

7.40

自引率

0.00%

发文量

448

审稿时长

16 weeks

期刊介绍： Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients. Specific topics covered in the journal include: ◦Epidemiology, detection and screening ◦Cellular research and biomarkers ◦Identification of biotargets and agents with novel mechanisms of action ◦Optimal clinical use of existing anticancer agents, including combination therapies ◦Radiation and surgery ◦Palliative care ◦Patient adherence, quality of life, satisfaction The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews & evaluations, guidelines, expert opinion and commentary, and case series that shed novel insights on a disease or disease subtype.